Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges
- Conditions
- Alzheimer DiseaseMild Cognitive ImpairmentDementia
- Registration Number
- NCT06347172
- Lead Sponsor
- Brigham and Women's Hospital
- Brief Summary
The objectives of this study are to demonstrate the feasibility of implementing a deprescribing nudge intervention using pragmatic methods, confirm that outcomes can be feasibly measured and evaluated at scale in a subsequent embedded pragmatic clinical trial (ePCT), and explore representativeness of persons living with dementia and care partners identified.
- Detailed Description
The PCP nudge will consist of: a 'pre-commitment' EHR nudge triggered when a PCP opens a patient encounter (i.e., prompt to first have a discussion and then later deprescribe) and a brief message within the in-basket prior to upcoming visits including information about their patient. The patient living with dementia (PLWD)/care partner nudge will include an electronic message delivered prior to upcoming visits (in their primary language recorded in the EHR) that includes a recommendation for the PLWD (and care partner, if available) to discuss medications with the PCP at the visit.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 360
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Composite of the percentage of eligible PCPs or their PLWD/care partners who view or click on information On or before the primary care provider visit This will be the primary progression criteria for the study and measured and evaluated separately by patient and provider.
- Secondary Outcome Measures
Name Time Method Number of nudges that fire as intended: Fidelity On the primary care provider visit Number of nudges that fired as intended
Discontinuation or prescribed reduction in medication Within 60 days after the primary care provider visit Discontinuation or prescribed reduction in dose of at least one high-risk medication of interest within 60 days after the visit.
Trial Locations
- Locations (1)
Mass General Brigham
🇺🇸Boston, Massachusetts, United States
Mass General Brigham🇺🇸Boston, Massachusetts, United StatesJulie Lauffenburger, PharmD, PhDContactjlauffenburger@bwh.harvard.edu